Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 1 of 1
Full-Text Articles in Medicine and Health Sciences
Randomized Phase Iii Trial Of Piroxicam In Combination With Mitoxantrone Or Carboplatin For First-Line Treatment Of Urogenital Tract Transitional Cell Carcinoma In Dogs., Sara D. Allstadt, C O. Rodriquez, B Boostrom, R B. Rebhun, K A. Skorupski
Randomized Phase Iii Trial Of Piroxicam In Combination With Mitoxantrone Or Carboplatin For First-Line Treatment Of Urogenital Tract Transitional Cell Carcinoma In Dogs., Sara D. Allstadt, C O. Rodriquez, B Boostrom, R B. Rebhun, K A. Skorupski
Sara Allstadt, DVM, Diplomate ACVIM (Oncology)
BACKGROUND: Reported response rates of transitional cell carcinoma (TCC) in dogs to piroxicam in combination with either mitoxantrone or carboplatin are similar; however, it is unknown whether either drug might provide superior duration of response. HYPOTHESIS/OBJECTIVES: To determine if the progression-free interval (PFI) of dogs with TCC treated with mitoxantrone and piroxicam was different than that of dogs receiving carboplatin and piroxicam. The hypothesis was that the efficacy of mitoxantrone is no different from carboplatin. ANIMALS: Fifty dogs with TCC without azotemia. METHODS: Prospective open-label phase III randomized study. Either mitoxantrone or carboplatin was administered every 3 weeks concurrently with …